Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Common Equity: 2015-2025

Historic Common Equity for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to $748.4 million.

  • Intellia Therapeutics' Common Equity fell 22.25% to $748.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $748.4 million, marking a year-over-year decrease of 22.25%. This contributed to the annual value of $872.0 million for FY2024, which is 16.97% down from last year.
  • Per Intellia Therapeutics' latest filing, its Common Equity stood at $748.4 million for Q3 2025, which was up 4.64% from $715.3 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Common Equity high stood at $1.2 billion for Q4 2022, and its period low was $494.8 million during Q2 2021.
  • Its 3-year average for Common Equity is $951.7 million, with a median of $971.1 million in 2024.
  • Per our database at Business Quant, Intellia Therapeutics' Common Equity soared by 235.87% in 2021 and then dropped by 26.34% in 2025.
  • Over the past 5 years, Intellia Therapeutics' Common Equity (Quarterly) stood at $1.0 billion in 2021, then rose by 18.78% to $1.2 billion in 2022, then declined by 15.01% to $1.1 billion in 2023, then dropped by 16.97% to $872.0 million in 2024, then declined by 22.25% to $748.4 million in 2025.
  • Its last three reported values are $748.4 million in Q3 2025, $715.3 million for Q2 2025, and $779.9 million during Q1 2025.